NEW YORK, United States —
Pfizer forecast more than
$50 billion in 2022 sales for its COVID-19 vaccine and therapeutic on Tuesday
as the giant pharma company reported a more than doubling of annual profits on
strong vaccine sales.
اضافة اعلان
Pfizer, which with German company
BioNTech won approval for
the first vaccine to counter the deadly virus, sees slightly lower 2022
revenues for the vaccine compared the just-finished year, but a big infusion of
revenues from Paxlovid, the company's pill for COVID-19.
"2021 was a watershed year for Pfizer," said Chief
Executive Albert Bourla in a statement. "Our successes in leading the
fight against COVID-19 have not only made a positive difference in the world; I
believe they have fundamentally changed our company forever."
Pfizer reported annual profits of $22 billion, more than
double the 2020 level. Annual revenues nearly doubled to $81.3 billion, with
$36.8 billion from the COVID-19 vaccine.
The results are the latest to show how the coronavirus has
transformed Pfizer, which a year ago had projected just $15 billion in
COVID-19 vaccines sales in 2021 and ended up selling more than twice that amount after
repeatedly lifting the forecast.
For 2022, Pfizer expects $32 billion in revenue from
COVID-19 vaccines and $22 billion in revenues from Paxlovid.
Bourla said the company is currently working on a new
Omicron-based vaccine candidate for COVID-19, as well as a new "potential
next-generation oral COVID-19 treatment."
The company expects to produce 120 million treatment courses
for
Paxlovid, with 6 million in the first quarter and 30 million the first half
of 2022.
Pfizer's scientists "continue to monitor the
COVID-19 virus and believe it is unlikely that it will be fully eradicated in the
foreseeable future," Bourla said.
"That said, we now have the tools — in the forms of
vaccines and treatments — that we believe will help enable us to not only
better manage the pandemic but also help countries move into the endemic
phase," Bourla said.
"In other words, we believe these tools will help allow
us to go back to normality and spend time with family and friends, travel,
attend indoor dining and concerts, and enjoy many other activities while
lowering the risk of overburdening hospitals and healthcare systems around the
world."
Although Pfizer's profit per share topped analyst
expectations, revenues fell short.
The company projected 2022 revenues of between $98 and $102
billion.
Shares fell 5.2 percent to $50.42 in early trading.
Read more Business
.jpg)
.jpg)
